VIPoma other imaging findings: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{VIPoma}} | {{VIPoma}} | ||
{{CMG}}{{AE}}{{PSD}} | |||
{{CMG}} | |||
==Overview== | ==Overview== | ||
Other imaging studies for VIPoma include [[ultrasound]] and [[somatostatin]] receptor scintigraphy. | |||
==Other Imaging Findings== | ==Other Imaging Findings== | ||
[[Somatostatin]] receptor [[scintigraphy]] is used to localise the [[tumor]], which is usually [[metastasis|metastatic]] at presentation. | [[Somatostatin]] receptor [[scintigraphy]] is used to localise the [[tumor]], which is usually [[metastasis|metastatic]] at presentation. | ||
| Line 13: | Line 10: | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Endocrinology]] | [[Category:Endocrinology]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
Revision as of 14:34, 21 October 2015
|
VIPoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
VIPoma other imaging findings On the Web |
|
American Roentgen Ray Society Images of VIPoma other imaging findings |
|
Risk calculators and risk factors for VIPoma other imaging findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]
Overview
Other imaging studies for VIPoma include ultrasound and somatostatin receptor scintigraphy.
Other Imaging Findings
Somatostatin receptor scintigraphy is used to localise the tumor, which is usually metastatic at presentation.